Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$10.85 USD
+0.07 (0.65%)
Updated May 24, 2024 04:00 PM ET
Pre-Market: $11.09 +0.24 (2.21%) 8:48 AM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Maravai LifeSciences Holdings, Inc. [MRVI]
Reports for Purchase
Showing records 61 - 72 ( 72 total )
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Big Guide for FY21; Increasing Momentum Into FY22: Raise PT from $39 to $46
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Life Science Tools: Hard and Soft Landings for COVID-19 Diagnostics and Vaccines
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Bioproduction: Three "Nuggets" from Earnings Season - Growth, Inflection Point & Decline
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Accelerating Vaccine Deployment and Increasing mRNA Potential - Raising PT to $39
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Modeling COVID-19: Vaccine and Diagnostic Demand Outlook with Herd Immunity in 2021
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Initiating Coverage with OW Rating - mRNA Potential More Attractive Than COVID-19 Vaccine
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department